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Background. Fusidic acid (FA) has been used for decades for bone infection, including prosthetic joint infection (PJI), often in
combination with rifampin (RIF). An FA/RIF pharmacokinetic interaction has not previously been described.
Methods. In a phase 2 open-label randomized study, we evaluated oral FA/RIF vs standard-of-care (SOC) intravenous antibi-
otics for treatment of hip or knee PJI. Outcome assessment occurred at reimplantation (week 12) for subjects with 2-stage exchange,
and after 3 or 6 months of treatment for subjects with hip or knee debride and retain strategies, respectively.
Results. Fourteen subjects were randomized 1:1 to FA/RIF or SOC. Pharmacokinetic profiles were obtained for 6 subjects
randomized to FA/RIF. FA concentrations were lower than anticipated in all subjects during the first week of therapy, and at
weeks 4 and 6, blood levels continued to decline. By week 6, FA exposures were 40%–45% lower than expected.
Conclusions. The sponsor elected to terminate this study due to a clearly illustrated drug–drug interaction between FA and RIF,
which lowered FA levels to a degree that could influence subject outcomes. Optimization of FA exposure if used in combination with
RIF should be a topic of future research.
Clinical Trials Registration. NCT01756924.
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Joint replacement surgery has become increasingly common,
and as the population ages, the burden of prosthetic joint infec-
tion (PJI) is projected to increase. CEM-102 (sodium fusidate,
fusidic acid), hereafter referred to as FA, is the only marketed
member of a novel class of natural product antibiotic, the fusi-
danes, initially identified from Fusidium coccineum in 1960 [1].
Fusidic acid binds with the ribosomal translocase, elongation
factor G (EF-G), preventing the dissociation of the EF-G-DP
complex from the ribosome, inhibiting protein synthesis and
bacterial growth [2–4]. Oral and topical FA have been used in
various countries in Western Europe for >4 decades to treat
staphylococcal infections.
FA has potent in vitro activity against gram-positive aerobic or-
ganisms. Antimicrobial activity against staphylococci recovered
from US subjects with blood, bone and joint, respiratory tract,
and skin infections as part of a surveillance study conducted in
2014 showed that FA inhibited 99.8% of 1804 Staphylococcus
aureus isolates (and 100.0% of 848 methicillin-resistant S. aureus
[MRSA] isolates) at a minimum inhibitory concentration
(MIC)≤ 1 µg/mL (minimum inhibitory concentration for which
90% of isolates inhibited [MIC90] = 0.12 µg/mL for both) [5].
The majority of coagulase-negative staphylococci were similarly
susceptible (MIC90 = 0.25 µg/mL). Among other gram-positive
bacteria, FA has activity against enterococci (MIC90 = 4 mg/L)
[6], Corynebacterium species (MIC ≤ 0.12 µg/mL) [7], Micro-
coccus luteus (MIC ≤ 0.5 µg/mL) [7], Streptococcus pyogenes
(MIC90 = 8 µg/mL) [6], and Propionibacterium species (MIC90-
= 1 µg/mL) [8].
Rifampin (RIF) has emerged as a valuable antibiotic in the
treatment of PJIs, due to its unique activity in the setting of bac-
terial biofilms. In a landmark study, Zimmerli and colleagues [9]
demonstrated the role of RIF in the effective treatment of PJI
when used in combination with initial intravenous therapy and
follow-on oral antibiotic therapy. However, RIF cannot be used
as monotherapy due to the high rate of resistance emergence
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when used alone [10]. FA has also demonstrated activity against
S. aureus biofilms in vitro, both as a single agent and in combi-
nation with daptomycin, vancomycin, or linezolid [11].
The combination of FA and RIF to treat PJIs has demonstrat-
ed efficacy and safety [12, 13], at doses similar to those used in
this study. To date, however, there have been no pharmacoki-
netic (PK) reports of FA and RIF given in combination, either
from a healthy volunteer drug–drug interaction (DDI) study or
from patients receiving combination therapy. The purpose of
this phase 2 trial was to assess the safety, tolerability, efficacy,
and PK of oral FA and RIF when used in combination com-
pared with intravenous standard-of-care (SOC) antibiotic ther-
apy, for the treatment of hip or knee PJI or spacer infection.
METHODS
Study Design
This was a phase 2, open-label, multicenter, randomized study
to evaluate oral FA plus RIF compared to SOC antibiotics for
the treatment of PJI (hip or knee) or spacer infections, in sub-
jects managed by 2-stage surgical exchange or debridement and
retention (DAR) strategies. One hundred subjects were to be
enrolled with the goal of randomizing 50 subjects (25 subjects
per treatment arm). PK blood sampling was performed for
subjects randomized to FA/RIF.
A randomized discontinuation study design allowing assess-
ment of FA/RIF tolerability prior to randomization was utilized
(Supplementary Figure 1). Enrolled subjects received loading
doses of FA and RIF in addition to intravenous SOC antibiotic
therapy initiated at the time of explant surgery or DAR. Subjects
meeting criteria for randomization (FA/RIF tolerability and
positive microbiological assessment) were randomized 1:1 to
either the FA/RIF or SOC arm.
Intraoperative cultures were obtained at the time of debride-
ment or explant surgery and at the time of prosthesis reimplan-
tation. Treatment continued for 6 weeks in subjects managed by
2-stage surgical exchange, and 3 or 6 months for hip or knee
DAR, respectively. Clinical outcome was assessed on the day
of reimplantation surgery (around week 12) for subjects
managed with 2-stage exchange and, for subjects with hip or
knee infection managed with DAR, at the end of scheduled
treatment, which was 3 or 6 months, respectively.
Study Population
Adults ≥18 years of age with prosthetic knee or hip joint or
spacer infection, with recent or planned surgery (2-stage ex-
change or DAR surgery), and suitable for oral antibiotic therapy
were enrolled. For randomization, all isolated gram-positive or-
ganisms must have been susceptible to FA, and all staphylococ-
cal isolates must have also demonstrated susceptibility to RIF.
Isolation of gram-negative bacteria or fungi was exclusionary.
Antibacterial Treatment
All subjects had received SOC intravenous antibiotics at the
time of randomization. Subjects were randomized 1:1 to either
oral FA plus RIF or SOC intravenous antibiotics, in accordance
with the Infectious Diseases Society of America clinical practice
guidelines for PJI [14] and local standard practice. FA was
administered orally as 2 loading doses of 1500 mg 12 hours
apart on day 1, followed by 900 mg twice daily thereafter. The
FA maintenance dose was later lowered to 900 mg in the morn-
ing and 600 mg in the evening or vice versa (1500 mg total daily
dose) to improve tolerability, and temporary FA dose reduction
to 600 mg twice daily in response to poor tolerability was per-
mitted. RIF was administered orally as 450 mg twice daily. Dose
reduction to 300 mg twice daily for subjects weighing <80 kg,
with estimated creatinine clearance of 30–50 mL/minute, with
poor tolerability, or at the investigator’s discretion, was permit-
ted. Treatment continued for 6 weeks in subjects managed by
2-stage surgical exchange, and 3 or 6 months for hip or knee
DAR, respectively. Chronic suppressive therapy was allowed
thereafter.
Pharmacokinetic Evaluations
Plasma for FA/RIF PK was collected on 3 days: approximately
day 7, and at weeks 4 and 6. Samples were drawn prior to
dosing, at 1, 2, and 4 hours postdose and 6–8 hours postdose.
Plasma concentrations of FA and of RIF and its metabolite,
25-desacetyl rifampin, were determined using sensitive and
selective, validated liquid chromatography–tandem mass spec-
trometry (LC-MS/MS) methods. Assays were performed by
Microconstants, Inc (San Diego, California). Where feasible,
plasma concentration-time data were analyzed by noncompart-
mental analysis using Phoenix/WinNonlin version 6.3 (Phar-
Sight Corporation, Mountain View, California).
Clinical Response
The primary outcome (clinical success, clinical failure, or inde-
terminate status) was determined by the investigator at the test-
of-cure (TOC) visit. Clinical success was defined as no evidence
of infection, by cultures obtained at prosthesis reimplantation,
arthrocentesis, arthroscopy, or arthrotomy, in a subject whose
antibiotic therapy was not changed (other than dose adjust-
ments). The TOC assessment occurred at reimplantation
(around week 12) for subjects with a 2-stage exchange, and
after 3 or 6 months of treatment for subjects with a hip or
knee DAR, respectively.
RESULTS
Demographics and Subject Disposition
A total of 41 subjects were enrolled between April 2013 and
April 2014. Twelve subjects were enrolled but not dosed (did
not meet protocol criteria for study drug dosing); 15 subjects
were enrolled, dosed, but not randomized; and 14 subjects
were enrolled, dosed, and randomized (7 to FA/RIF and 7 to
SOC) (Supplementary Figure 2). Baseline characteristics for
the 14 enrolled, dosed, and randomized subjects (safety–intent-
to-treat population) are presented in Table 1.
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Four randomized subjects (n = 2 [28.6%] from each arm)
prematurely withdrew from the study before TOC (Table 2),
2 subjects on the SOC arm due to early termination of the
study by the sponsor. One subject (n = 1 [14.3%]) randomized
to SOC prematurely discontinued SOC study drug due to an
adverse event (AE) (vancomycin-associated fever), and 1 sub-
ject (n = 1 [14.3%]) randomized to FA/RIF prematurely discon-
tinued study drug due to AEs of nausea and diarrhea.
Efficacy Results
Due to early study closure, the availability of efficacy data are
limited. Of 7 subjects enrolled in each treatment arm, therapy
was considered successful at the TOC visit in 4 subjects in
each arm (Table 1). However, 2 of the FA/RIF subjects were cul-
ture negative at enrollment (therapy was considered successful
for 1), and 2 of the SOC subjects did not reach TOC due to early
study closure; therefore, final determination of their outcome is
not possible, even though they might have ultimately been
successes.
Of particular interest, 1 subject in the FA/RIF group
with MRSA (subject 114-06) demonstrated microbiological
treatment failure. For that subject, the MRSA strain isolated
at the initial explant surgery was susceptible to both FA
(MIC = 0.12 µg/mL) and RIF (MIC = 0.25 µg/mL). On the day
of reimplantation surgery (day 105), a MRSA strain resistant to
RIF (MIC = 8 µg/mL) was recovered from 2 tissue biopsies, but
the isolates remained susceptible to FA (MIC = 0.06 µg/mL).
This microbiological failure was potentially related to depressed
FA levels due to a DDI (described below), resulting in essential-
ly RIF monotherapy. This subject (114-06) had the lowest FA
plasma concentrations of all the subjects at week 1 (taking
1800 mg FA total daily dose) and at week 4 (taking 1500 mg
FA total daily dose) (Figure 1).
Safety Results
Similar to efficacy, due to early study closure, the safety database
is limited. Gastrointestinal disorders of mild or moderate
Table 1. Baseline Characteristics for Safety-Intent-to-Treat Population and Outcome
Subject
ID Age, y Sex
Site of PJI
Infection
Surgical
Procedure
Baseline Inclusionary
Pathogen
Baseline FA/RIF
MIC, µg/mL
Randomized
Therapy Outcome Reason for Failure
103-01 62 M Hip 2-stage exchange MSSA 0.12/0.03 FA/RIF Success
103-02 64 M Hip DAR MRSA 0.12/0.015 FA/RIF Failure AE; switched to new
antibiotic
108-07 75 M Knee 2-stage exchange Culture negative NA FA/RIF Failure Persistent inflammation
111-01 66 F Knee 2-stage exchange Staphylococcus
epidermidis
0.25/0.015 FA/RIF Success
112-04 64 F Knee 2-stage exchange No inclusionary
pathogens
NA FA/RIF Success
114-03 86 F Knee 2-stage exchange MSSA 0.12/0.015 FA/RIF Success
114-06 72 M Knee 2-stage exchange MRSA 0.12/0.25 FA/RIF Failure Infection recurrence
(MRSA resistant to
RIF)
103-03 45 M Hip & spacer DAR & spacer
replacement
MRSA . . . SOC Indeterminate Insufficient data; study
discontinued
104-08 62 M Knee 2-stage exchange S. epidermidis . . . SOC Success
108-04 65 M Knee 2-stage exchange S. epidermidis . . . SOC Failure AE; switched to new
antibiotic
108-06 83 M Knee 2-stage exchange Group B streptococci . . . SOC Success
108-08 64 F Hip 2-stage exchange Culture negative . . . SOC Indeterminate Insufficient data; study
discontinued
114-05 61 M Knee 2-stage exchange S. epidermidis . . . SOC Success
114-07 77 F Hip & spacer 2-stage exchange MSSA . . . SOC Success
Abbreviations: AE, adverse event; DAR, debridement and retention; FA, fusidic acid; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus; NA, not applicable; PJI, prosthetic joint infection; RIF, rifampin; SOC, standard of care.
Table 2. Subject Disposition for Safety–Intent-to-Treat Population
Subject Disposition
FA/RIF, No.
(%)
SOC, No.
(%)
Safety-ITT population (randomized subjects who
received at least 1 dose of study drug)
7 7
Subjects who completed study 3 (42.9) 1 (14.3)
Subjects prematurely withdrawing from study
prior to TOC
2 (28.6) 2 (28.6)
Reason for premature withdrawal
Noncompliance with protocol-required
procedures
1 (14.3) 0 (0.0)
Sponsor decision 1 (14.3) 1 (14.3)
Other 0 (0.0) 1 (14.3)
Subjects who completed study drug 5 (71.4) 6 (85.7)
Subjects prematurely discontinuing study drug 2 (28.6) 1 (14.3)
Reason for premature discontinuation from study drug
Adverse event 1 (14.3) 1 (14.3)
Development of a clinically significant
laboratory abnormality
1 (14.3) 0 (0.0)
Abbreviations: FA, fusidic acid; ITT, intent to treat; RIF, rifampin; SOC, standard of care; TOC,
test of cure.
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intensity were reported most frequently by both treatment
groups, the most common being nausea and diarrhea.
Pharmacokinetic Results
Pharmacokinetic data for 6 of 7 FA/RIF-treated subjects were
obtained and a summary of the dosing prior to each PK day
is shown in Table 3. Concentration-time data were analyzed
using noncompartmental approaches as implemented in
WinNonLin Phoenix (Certara). Because FA dose reductions
to 600 mg twice daily were permitted, PK parameters were
dose-normalized using the subject’s dose the week prior to
the PK assessment, and dose-normalized parameters were
used to determine the change in exposure from week 1 at
weeks 4 and 6. The mean FA (dose normalized) percentage
decrease in area under the concentration-time curve (AUC)
was 43% at week 4 and 45% at week 6 (Figure 2). One subject
(subject 111-01) did not receive RIF after week 4, so week 6 data
were excluded from PK analysis of a potential DDI.
The mean RIF maximum plasma concentration (Cmax) on
week 4 was approximately 34% lower than week 1, while the
week 6 Cmax was approximately 42% lower than week 1. The
mean RIF AUC on week 4 was approximately 45% lower than
week 1, while the week 6 AUC was approximately 47% lower
than week 1 (not shown).
Based on a prior phase 1 PK study with FA (using a loading
dose of 1650 mg twice daily and maintenance dose of 825 mg
twice daily), the expected steady-state trough concentrations
were 200 µg/mL [15]. As shown in Figure 1, FA concentrations
were lower than anticipated in all subjects during the first week
of therapy and, at weeks 4 and 6, FA blood levels continued to
decline. By week 6, FA exposures were 40%–45% lower than
previously observed exposures with similar dosing regimens,
suggesting a substantial DDI in which RIF lowers FA
concentrations.
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Figure 1. By subject (hours post-AM dose) fusidic acid plasma concentrations. Subject 111-01 discontinued rifampin at week 4 due to intolerance. Actual plasma concen-
trations are plotted. Abbreviation: PK, pharmacokinetic.
Table 3. Summary of Study Drug Administration in Subjects Randomized
to Fusidic Acid/Rifampin
Subject
FA Total Daily Dose, mg RIF Total Daily Dose, mg
Hospital
Discharge
Week
4
Week
6
Hospital
Discharge
Week
4
Week
6
111-01 1800 1200 1200 900 300 0
114-03 1800 1200 1500 600 600 600
103-01 1800 1800 1800 900 900 900
114-06 1800 1500 1500 900 900 900
108-07 1200 1200 1500 600 600 600
112-04 1500 1500 1200 900 900 900
Abbreviations: FA, fusidic acid; RIF, rifampin.
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The observation of a DDI is clearly illustrated in the FA plas-
ma concentrations of subject 111-01 (Figure 1). At the time of
hospital discharge on day 5, this subject had an FACmax of 95.6
µg/mL and AUC(0–t) of 581 µg × h/mL, having received FA
1800 mg total daily dose (TDD) and RIF 900 mg TDD. Follow-
ing hospital discharge, a dose adjustment to FA 1200 mg TDD
and RIF 300 mg TDD was made to manage gastrointestinal in-
tolerance. At week 4, the FA Cmax and AUC(0–t) had decreased
substantially, to 64.6 µg/mL and 292 µg × h/mL, respectively. At
this visit, RIF was discontinued due to elevated bilirubin and the
subject continued on FA monotherapy. By week 6, when the
subject was only taking FA 1200 mg TDD, the FA plasma con-
centration levels markedly increased, to a Cmax and AUC(0–t) of
117 µg/mL and 658 µg × h/mL, respectively. This Cmax was
more consistent with steady-state plasma concentrations ob-
served with a similar dosing regimen in the phase 1 PK study
[15]. Antimicrobial therapy was successful in this subject.
DISCUSSION
When coadministered with RIF, a decline in FA plasma levels
occurred by day 5–7 and worsened through weeks 4 and
6. These levels were lower than the expected steady-state trough
concentrations based on phase 1 PK data. The likely mechanis-
tic explanation for the interaction is induction of cytochrome
P450 3A4 (CYP3A4) by RIF. As FA is metabolized primarily
by CYP3A4, coadministration results in more rapid metabolism
of FA. Not illustrated in this article, as it has been well described
in the literature, a decline in RIF plasma levels over time was
also observed in our study, and is likely due to autoinduction
of metabolism [16]. Although the interaction between FA and
RIF may seem predictable, clinical practice over the past decade
has supported use of this antibiotic combination [12, 13, 17].
When coadministered, a reduction in FA exposure creates an
opportunity for rapid emergence of RIF resistance and subse-
quent treatment failure. This may have occurred in 1 subject as-
signed to the FA/RIF group; MRSA initially recovered during
explant surgery was susceptible to both FA and RIF. On day
105 at reimplantation surgery, MRSA, now resistant to RIF
with an MIC of 8 µg/mL (however, still susceptible to FA),
was again recovered. This single case mirrors the experience
of Drancourt [13], in which FA/RIF was as effective as ofloxa-
cin/RIF; however, treatment failures were typically associated
with emergent staphylococcal RIF resistance, but not FA resis-
tance. Treatment guidelines for PJI include the recommenda-
tion for RIF along with a second antibiotic [14]. Specifically,
the practice of using RIF plus FA is supported by data from 1
randomized controlled trial [13] and 2 retrospective studies [12,
18]. However, it should be noted that aggressive surgical de-
bridement and intravenous antibiotics to reduce the bacterial
burden prior to long-term oral antibiotic therapy likely contrib-
uted to the high clinical success rate (90%) observed in the
Aboltins study [12]; and the importance of these interventions
should not be understated. Furthermore, as discussed in this ar-
ticle, the combination of FA with RIF presents PK challenges.
To summarize, the sponsor elected to terminate this study
due to a clearly illustrated DDI between FA and RIF, which low-
ered FA levels to a degree that could influence subject outcomes.
The combination of FA and RIF has been used for the treatment
of PJI in many parts of the world for decades; however, based on
these PK data, optimization of FA exposure if used in combina-
tion with RIF should be a topic of future research.
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Figure 2. Box-and-whisker plot of dose-normalized (DN) area under the concentration-time curve from time zero to last measurable concentration-time point (AUCt) and
maximum plasma concentration (Cmax) of fusidic acid, by week. Outliers of the distributions are not shown. Subject 111-01 at week 6 was not included in this analysis because
this subject did not receive rifampin after week 4, and data do not contribute to the evaluation of the drug–drug interaction.
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Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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